Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapeutics > Exam 3 lecture 5 > Flashcards

Exam 3 lecture 5 Flashcards

1
Q

disease progression of PD

A

Develops over 5-10 years with an increase in motor symptoms.
Cognitive symptoms may be present after several years of PD
Life expectancy after diagnosis is 15 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

clinical presentation of PD (motor)

A

Tremor
bradykinesia
rigidity
parkinsonian gait (walking style)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical presentation of PD (non motor)

A

Anxiety and depression
constipation
dementia
insomnia
Psychosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

non pcol tx of PD

A

Exercise/physical therapy
nutritional counseling
occupational therapy
psychotherapy
speech therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pcol tx of pd

A

1st line- rule out drug induced PD

Dopamine precursor
dopamine agonist
MAO-B inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Rank drug efficacy with motor symptoms

A

Levodopa/carbidopa>DA>MAOB-I

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

for most PD pts we initiate

A

Levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When to use dopamine agonist? WHen to avoid dopamine agonist?

A

Dopamine agonist may be used as initial tx if age<60 yrs and higher risk for dyskinesia

Avoid dopamine agonist as initial tx if
age>70
history of ICD
cognitive impairement
excessive daytime sleepiness
hallucinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the dopamine precursor used in PD

A

CD/LD (carbidopa/levidopa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

place in therapy for PD for LD/CD

A

1st line for initial PD therapy

most effective monotherapy “gold standard”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

side effects of LD/CD (!)

A

N/V
LD motor fluctuations/dyskinesia
hallucinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

starting dose of LD/CD (!)

A

25/100 mg CD/LD PO BID-TID with meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are LD motor fluctuations (!)

A

wearing off
Freezing
Delayed onset
peak dose dyskinesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Define the LD motor fluctuations (!!)

A

wearing off- before next dosing interval, signs of motor symptoms
freezing- inability to move due to insufficient or fluctuating DA levels
Delayed onset- Therapeutic benefits delayed
Peak-dose dyskinesias- Involuntary body movement caused by high DA levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the types of dopamine agonists used to treat PD

A

ergots and non ergots

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name none ergot dopamine agonists

A

pramiprexole
ropinirole
rotigotine
apomorphine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

strating doses for non ergot dopamine agonists

A

pramipexole IR 0.125 mg PO TID; ER 0.375 mg PO daily

  • ropinirole IR 0.25 mg PO TID; ER 2 mg PO daily
  • rotigotine 2 mg patch applied to the skin Q24H
  • apomorphine 2 mg SC injection prn up to 5 x daily or
    10 mg SL Film up to 5 x daily
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

place in therapy for non ergot DA agonists? What is used more, ergots or non ergots? Why?

A

1st line for initial PD therapy

non ergots used more because they are less likely to cause LD motor fluctuations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are MAO-B i drugs? When are they used?

A

Rasagiline
Selegiline
Safinimide

less effective at controlling motor symotoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

place in therapy for MAO-B I drugs

A

1st line for mild symptoms of PD
2nd line for adjunct

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

starting doses of MAO-B I drugs

A

Rasagiline- 0.5 mg po
Selegiline- 5 mg PO BID
Safinamide- 50 mg PO QD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What drug drug i/a should we be aware of with MAO B i

A

serotonergic antidepressants
dextromethorphan
serotonergic opioids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

COMT i MOA

A

Minimize breakdown of dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

COMT i drugs and place in therapt

A

entacapone
opicapone
tolcapone

in combo with levodopa/carbidopa. PRevents wearing offS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

S/E of COMT i drugs

A

N/V
brown/orange urine discoloration for entacapone (!!!!!)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

treatment initiation and flow for PD

A

Non pharm always first

DOPAMINE PRECURSOR (most)

(2nd line- DA, MAO-B, COMT)

MAO-B (contingent)
(2nd line- DA, dopamine precursor)

DA (contingent)
(2nd line MAO-B and COMT)

27
Q

Pros, cons and who of dopamine agonists

A

pros- once daily dosing formulations
better tolerated by younger patients
limited by motor fluctuations

cons- expensive
less symptomatic benefits than CD/LD
many adverse effects

who- age <60 at higher risk of dyskinesia

28
Q

Avoid dopamine agonists if

A

age>70
hallucinations
ICD
cognitive impairement
excessive daytime sleepiness

29
Q

pros, cons, who of CD/LD

A

pros- gold standard due to symptomatic benefit
cheap
variety of dosage forms

cons- motor fluctuations
dosing frequency (can be >3x per day)
who- most

30
Q

pros, cons, who of MAO-B

A

pros- generally well tolerated
delays onset of motor fluctuation

cons- least effective agent against motor symptoms
dietary restriction (risk serotonin syndrome)

who- high risk of motor fluctuations
minor sx

31
Q

Develop a therapeutic plan to manage levodopa-induced
motor fluctuations (!!!) wearing off

A

wearing off- increase CD/LD doe or frequency
add DA agonist, MAOI or COMTI
XR CD/LD

32
Q

Develop a therapeutic plan to manage levodopa-induced
motor fluctuations (!!!) freezing

A

increase CD/LD dose or frequency
add DA agonist
Add ODT CD/LD

33
Q

Develop a therapeutic plan to manage levodopa-induced
motor fluctuations (!!!) delayed onset

A

Take CD/LD on empty stomach
ODT CD/LD
void CR/XR CD/LD

34
Q

Develop a therapeutic plan to manage levodopa-induced
motor fluctuations (!!!) peak dose dyskineses

A

Add amantidine
lower dose of DA or CD/LD

35
Q

Recommend management of non-motor symptoms for a
patient with PD (!!!)

A

constipation- evaluate for meds causing constipation
increase fluid intake, physical actvity
stool softener/ axatives or probiotics

Insomnia- melatonin
AVoid benzodiazepines (diazepam, lorazepam,
oxazepam)

orthostatic HTN- Non- pcol counseling
midrodrine, droxidopa
Medical equipment to stabilize it

Anxiety/depression- Avoid benzodiazepines,
CBT (cognitive behavioral therapy)
SSRI/SNRI

dementia- cholinesterase inhibitor (donepezil, rivastigamine)
avoid anticholinergics, benzodiazepines,
antihistamines, sedatives)

Psychosis/delirium- Avoid- haloperidol, olanzepine,
plaiperidone, risperidone

36
Q

What are the cardinal signs of AD? Seen more in men or women?

A

brain shrinkage, senile plaques, neurofibrillary tangles

seen more in females

37
Q

AD symptoms

A

memory loss (especially recent)

impaired ability to learn and reason

impaired ability to carry out daily activities, confusion and untidiness

anxiety, suspicion, hallucinations

motor dysfunction in later stages

38
Q

environmental risk factors for AD

A

low educational level
reduced mental activity in late life
reduced physical activity in late life
head injury
neuropathology (loss of brain volume)

39
Q

difference between amyloid plaques and neurofibrillary tangles

A

amyloid plaques- extracellular
neurofibrillary tangles- intracellular

amyloid plaques consist of amyloid B peptide (AB)
neurofibrillary tangles consist of hyper phosphorylated tau

40
Q

Neuropathology primarily affect areas of higher cognitive areas of higher cognitive function, what areas are these and what is affected? (AD)

A

entorhinal cortex- memory formation/consolidation)
Hippocampus- memory formation/consolidation
Basal forebrain- learning
neocortex- memory, learning cognition

41
Q

T/F pathology is causing synaptic degeneration (AD)

A

true

42
Q

What is synapse loss in AD mainly due to?

A

reduced levels of neurotransmitters, especially ach, but also serotonin, norepinephrine, dopamine

43
Q

What happens to neurons in areas close to neurofibrillary tangles and amyloid plaques

A

destruction of synaose

44
Q

Genetic evidence suggests which pathogenic molecule is key for AD (AB or TAU)

A

AB- amyloid plaques
TAU- neurofibrillary tangles

genetic evidence suggests AB

mutations in AB precursors are linked to early onset AD

45
Q

APP gene is located in which chromosome? What can this lead to

A

located in chromosome 21 (same one linked to downs syndrome)

can lead to AD like symptoms in 4th decade of life in trisomy 21 pts

46
Q

Aβ peptide is released from the transmembrane amyloid precursor protein (APP) by the activity of

A

β-secretase (BACE1) and γ-secretase.

47
Q

What happens if APP is cleaved by alpha secretase in middle of AB segment instead of β-secretase (BACE1) and γ-secretase.

A

Cleavage of APP by α-secretase in the middle of the Aβ segment releases a
non-amyloidogenic (non-toxic) fragment

48
Q

difference between Aβ42 and Aβ40

A

Aβ42 forms amyloid fibrils more readily than Aβ40.

49
Q

How is Aβ42 formed more that Aβ40 and what are the effects of this

A

Mutations in the APP gene favor cleavage by β- or γ-secretase, resulting in the
production of more Aβ42 relative to Aβ40.

  • Mutations in the gene encoding presenilin-1 or presenilin-2 (PSEN1 or
    PSEN2), which are components of the γ-secretase complex, alter APP cleavage
    by γ-secretase, resulting in the production of more Aβ42 compared to Aβ
50
Q

What does AB aggregation lead to? (!!)

A

AB aggregation is thought to promote tau hyperphosphorylation leading to neurofibrillary tangle formation, cytoskeleton and disruption of axonal trafficking

51
Q

why do anomalies with tau lead to disruption in cytoskeleton (!!)

A

Tau normal function is to be bound to microtubules and stabilize them. Anomalies affect this

In unhealthy areas where tangles have accumulated, the cytoskeletal
tracks are disrupted and disorganized, resulting in defects in axonal
transport that lead to synaptic dysfunction

52
Q

effect of AB aggregation on microglial activation

A

AB induces neurotoxicity indirectly by triggering microglial activation.

53
Q

what happens when microglia is activated by AB

A

Activated microglia release pro-inflammatory cytokines (e.g.
prostaglandins, interleukins, tumor necrosis factor-α) that cause neuroinflammation.

  • Activated microglia also release reactive nitrogen species (e.g. nitric
    oxide, peroxynitrite) and reactive oxygen species (superoxide,
    hydrogen peroxide) that cause oxidative stress
54
Q

Understand how ApoE genetics status modulates AD risk

A

There are three ApoE isoforms as a result of polymorphisms
in the ApoE gene: ApoE2, ApoE3, and ApoE4.

→ Individuals with one or two ApoE4 alleles have an increased
risk of AD, whereas inheritance of the ApoE2 allele
decreases AD risk

55
Q

Cholinesterase inhibitor use and drugs

A

Used to treat AD

Donepezil (aricept)
Rivastigimine
Galantamine

56
Q

MOA of donepezil, rivastigamine, galantamine

A

Donepezil- Specific reversible inhibitor of ach
rivastigamine- inhibits acetylcholinesterase and butyrylcholinesterase
galantamine- selective reversible inhibitor of achetylcholinesterase and enhances action of acetylcholine.

57
Q

Use antiglutaminergic agents and drugs?

A

Use- AD therapy

Memantine- NMDA antagonist that blocks glutamatergic
neurotransmission via a noncompetitive mechanism, reduces excitotoxicity

58
Q

what is glutamate

A

an excitatory neurotransmitter that is required for learning and memory

59
Q

Describe pathogenic mechanisms being targeted in the
development of new AD therapies.

A

1) AB targetting
2) non amyloid therapy

60
Q

AB therapy targets

A

AB- generation(b and gamma secretase inhibitors)
AB-aggregation- (inositol, polyphenols)
AB clearence- (AB antibody)

61
Q

non amyloid targets

A

Tau-kinase inhibitors
glutamate mediated excitotoxicity
inflammation of oxidative stress

62
Q

Understand how florbetapir (18F) and other imaging agents can be used to monitor amyloid formation in living individuals (what is florbetapir and how does it work)

A

18F is a radiolabled agent that binds B amyloid visualized by PET scanning

63
Q

Know similarities and differences between AD and other dementias (DLB, FTDP)

name and describe non AD dementias

A

Non-AD dementias

Vascular dementia- impaired judgement or executive function is a more common initial symptom than the memory loss characteristic of AD. Occurs as a result of brain injury associated with stroke.

Dementia with lewy bodies (DLB)- Combination of cognitive and parkinsonian symptoms. Visual hallucinations are core diagnostic features.

Front temporal dementia (FTD)- disinhibited behavior, poor impulse control, antisocial behavior. Neuropathology is characterized by presence of tau accumulations.

64
Q
A

Therapeutics (38 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions